Literature DB >> 16180144

Characterization of the ovine ortholog of secretory leukoprotease inhibitor.

Thomas I Brown1, Rohit Mistry, Robert Gray, Margaret Imrie, David D Collie, Jean-Michel Sallenave.   

Abstract

There is great interest in the use of the sheep as a model for the investigation of inflammation in the lung. The serine antiproteases secretory leukoprotease inhibitor (SLPI) and elafin are important "alarm antiproteases" in the lung and have potentially important roles in the innate immune response. SLPI was first characterized in man and subsequently in murine, porcine, and rat tissues. Here we present the first data concerning the gene and cDNA sequence encoding for the ovine ortholog of SLPI, a protein of 132 amino acids with 66% sequence identity at the amino acid level with human SLPI. A 24-amino-acid signal sequence signifies that, like the other mammalian orthologs, ovine SLPI is a secreted protein. Tissue distribution of expression is demonstrated by reverse transcription polymerase chain reaction (RT-PCR) and shows features similar to SLPI expression in other mammals, specifically at mucosal surfaces such as the upper respiratory and intestinal tracts, and also the skin, liver, and kidney. This distribution lends credence to SLPI having important roles in innate immunity. We have also cloned the ovine SLPI cDNA into an expression vector and expressed the ovine SLPI protein in vitro. This has enabled us to demonstrate that ovine SLPI is correctly processed (Western blot analysis and SELDI-TOF mass spectrometry analysis) and has biological antihuman neutrophil elastase activity. In summary, the ovine ortholog of SLPI shows similarities to other members of the SLPI family and has all the features of a modulator of innate immunity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16180144     DOI: 10.1007/s00335-005-0030-2

Source DB:  PubMed          Journal:  Mamm Genome        ISSN: 0938-8990            Impact factor:   2.957


  27 in total

1.  EXPERIMENTAL EMPHYSEMA: ITS PRODUCTION WITH PAPAIN IN NORMAL AND SILICOTIC RATS.

Authors:  P GROSS; E A PFITZER; E TOLKER; M A BABYAK; M KASCHAK
Journal:  Arch Environ Health       Date:  1965-07

2.  Location of the protease-inhibitory region of secretory leukocyte protease inhibitor.

Authors:  S P Eisenberg; K K Hale; P Heimdal; R C Thompson
Journal:  J Biol Chem       Date:  1990-05-15       Impact factor: 5.157

3.  Lipopolysaccharide-induced alveolar wall destruction in the hamster is inhibited by intratracheal treatment with r-secretory leukocyte protease inhibitor.

Authors:  J Stolk; A Rudolphus; J A Kramps
Journal:  Ann N Y Acad Sci       Date:  1991       Impact factor: 5.691

4.  Different susceptibility of elastase inhibitors to inactivation by proteinases from Staphylococcus aureus and Pseudomonas aeruginosa.

Authors:  M Sponer; H P Nick; H P Schnebli
Journal:  Biol Chem Hoppe Seyler       Date:  1991-11

5.  Secretion of mucus proteinase inhibitor and elafin by Clara cell and type II pneumocyte cell lines.

Authors:  J M Sallenave; A Silva; M E Marsden; A P Ryle
Journal:  Am J Respir Cell Mol Biol       Date:  1993-02       Impact factor: 6.914

6.  Inhibition of lipopolysaccharide-induced pulmonary emphysema by intratracheally instilled recombinant secretory leukocyte proteinase inhibitor.

Authors:  A Rudolphus; J Stolk; J H Dijkman; J A Kramps
Journal:  Am Rev Respir Dis       Date:  1993-02

7.  The cloning and characterization of a murine secretory leukocyte protease inhibitor cDNA.

Authors:  R J Zitnik; J Zhang; M A Kashem; T Kohno; D E Lyons; C D Wright; E Rosen; I Goldberg; A C Hayday
Journal:  Biochem Biophys Res Commun       Date:  1997-03-27       Impact factor: 3.575

8.  Molecular cloning and expression of cDNA for human antileukoprotease from cervix uterus.

Authors:  R Heinzel; H Appelhans; G Gassen; U Seemüller; W Machleidt; H Fritz; G Steffens
Journal:  Eur J Biochem       Date:  1986-10-01

9.  Secretory leucoprotease inhibitor prevents lipopolysaccharide-induced IkappaBalpha degradation without affecting phosphorylation or ubiquitination.

Authors:  Clifford C Taggart; Catherine M Greene; Noel G McElvaney; Shane O'Neill
Journal:  J Biol Chem       Date:  2002-06-25       Impact factor: 5.157

10.  Novel distribution of the secretory leucocyte proteinase inhibitor in kidney.

Authors:  S Ohlsson; I Ljungkrantz; K Ohlsson; M Segelmark; J Wieslander
Journal:  Mediators Inflamm       Date:  2001-12       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.